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During HSV-1 infection, IE gene expression triggers apoptosis, but subsequent synthesis of infected cell proteins blocks apoptotic death
from ensuing. This ‘‘HSV-1-dependent’’ apoptosis was identified in HEp-2/HeLa cells infected with wild-type HSV-1 in the presence of an
inhibitor of protein synthesis or a virus lacking ICP27 {HSV-1(vBSD27)}. Unlike HEp-2/HeLa cells, vBSD27-infected Vero cells fail to
exhibit dramatic apoptotic morphologies at times prior to 24 hpi. Here, we examined the basis of these different apoptotic responses to HSV-
1. We found that infected Vero cells take substantially longer than HEp-2/HeLa cells to display membrane blebbing, chromatin condensation,
DNA laddering, and PARP cleavage. Vero, but not HEp-2/HeLa, cells required de novo protein synthesis to exhibit efficient HSV-1-
dependent apoptosis, which included changes in mitochondrial membrane potential, and these factors were produced prior to 3 hpi. Vero cells
infected with recombinant viruses devoid of the ICP27 and ICP4 proteins alone or both the ICP27 and ICP22 proteins were apoptotic. These
results indicate a requirement for cellular or other viral protein synthesis in Vero cells and provide insight into cell type differences in HSV-1-
dependent apoptosis.
D 2005 Elsevier Inc. All rights reserved.Keywords: Apoptosis; Herpes simplex virus; Vero; HEp-2/HeLa; Protein synthesisIntroduction
Apoptosis is a highly regulated form of cell death that is
common to many physiological and pathological processes
(reviewed in Vaux and Strasser, 1996; White, 1996). During
apoptosis, a cascade of cysteinyl-aspartate-kinases (cas-
pases) is activated (reviewed in Salvesen and Dixit, 1997;
Villa et al., 1997). Initiator caspases activate effector
caspases that allow for the progression of apoptosis by
cleaving many cellular enzymes important for cell main-
tenance, e.g., a DNA repair enzyme, poly(ADP-ribose)po-
lymerase (PARP), and a DNAse inhibitor, DFF-45
(reviewed in Sanfilippo and Blaho, 2003). Ultimately, the
destruction of the cell via apoptosis leads to specific
morphological changes including chromatin condensation,
nucleosomal DNA fragmentation, disruption of mitochon-0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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E-mail address: john.blaho@mssm.edu (J.A. Blaho).drial membrane potential, and membrane blebbing (Kerr
and Harmon, 1991; Kerr et al., 1972; Wyllie et al., 1980).
Although much of the disease associated with herpes
simplex virus 1 (HSV-1) infection is due to the lysis of
infected cells, a subset of HSV-1-induced pathologies has
been reported to contain an apoptotic component. In one
study, Perkins et al. found that tissue sections from HSV-
associated acute focal encephalitis contained cells with
active caspase 3 and cleaved PARP (Perkins et al., 2003).
They also found that HSV-1 infection increased the levels of
these apoptotic markers in hippocampal cultures. Addition-
ally, investigators have reported the presence of apoptotic
cells in mouse (Zheng et al., 2001) and rabbit (Wilson et al.,
1997) eyes infected with HSV-1. These findings suggest that
modulation of apoptosis by HSV-1 might be important in
the development of herpetic disease.
HSV-1 first triggers HSV-1-dependent apoptosis and then
blocks apoptosis in infected cells in culture. Koyama et al.
were the first to identify that HEp-2/HeLa cells infected05) 274 – 290
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synthesis inhibitor, cycloheximide (CHX), die by apoptosis
(Koyama and Adachi, 1997). This indicated that HSV-1 was
able to trigger apoptosis in the absence of de novo
viral protein synthesis. Our laboratory demonstrated that
cells infected with UV-inactivated HSV-1 in the absence
or presence of CHX failed to die by apoptosis. Since
UV-irradiated viruses are capable of entry, deenvelopment,
and nuclear translocation, these activities are insufficient to
trigger apoptosis in infected cells (Aubert and Blaho, 1999;
Aubert et al., 1999; Sanfilippo et al., 2004). Recently, we
determined that the HSV apoptotic trigger requires tran-
scription of immediate early viral genes (Sanfilippo et al.,
2004). Additionally, we have found that the addition of
CHX prior to 3 h post-infection (hpi), but not after 6 hpi,
resulted in apoptosis of HSV-1-infected cells (Aubert et al.,
1999). Taken together, these data led us to conclude that
HSV-1 triggers apoptosis through a mechanism independent
of de novo protein synthesis and that between 3 and 6 hpi
infected cell proteins are produced which prevent apoptotic
death from ensuing (Aubert and Blaho, 2001; Goodkin et al.,
2004).
Several laboratories have identified viral genes which
play roles in apoptosis modulation by HSV-1. HSV-1 viral
replication is controlled by a coordinated cascade (reviewed
in Roizman and Sears, 1996), and transcriptional activation
by the IE gene products, especially ICP27 and ICP4, is
necessary for expression of the later viral genes and the
subsequent production of progeny virions (DeLuca and
Schaffer, 1985; DeLuca et al., 1985; Dixon and Schaffer,
1980; Hardwicke et al., 1989; McCarthy et al., 1989;
Preston, 1979; Rice and Knipe, 1990; Sacks et al., 1985;
Soliman et al., 1997; Watson and Clements, 1980). Infection
of cells with a mutant virus defective for both ICP4 and
US3, d120, leads to apoptosis (Galvan et al., 1999; Leopardi
and Roizman, 1996; Leopardi et al., 1997). A virus lacking
ICP27, vBSD27, also causes infected cells to die by
apoptosis (Aubert and Blaho, 1999). Furthermore, infection
with a series of viruses carrying mutations in ICP27 that
were incapable of transactivating early and leaky-late gene
expression led to apoptosis of infected cells (Aubert et al.,
2001). Infection with replication-defective viruses such as
these triggers apoptosis, but infected cell survival factors are
not produced, and the cells ultimately die by apoptosis. In
support of this conclusion, several other antiapoptotic HSV-
1 genes have been identified (Hagglund et al., 2002; Jerome
et al., 1999; Leopardi and Roizman, 1996; Perng et al.,
2000; Zhou and Roizman, 2002). The above findings led us
to propose a model in which there is a balance between the
trigger and the preventers of apoptosis during productive
HSV-1 infection (Aubert and Blaho, 2001; Goodkin et al.,
2004). Maintaining this balance allows productive viral
replication, which lyticly kills cells resulting in cytopathic
effect (CPE), whose features include cell swelling, nuclear
enlargement, marginalization of the cellular chromatin, and
cell lysis (Avitabile et al., 1995; Hampar and Elison, 1961;Heeg et al., 1986; Roizman, 1962; Roizman and Roanne,
1964; Roizman and Sears, 1996). When the balance is upset
due to a reduction in late viral protein synthesis, e.g.,
experimentally through the disruption of important IE viral
proteins or the addition of CHX, it results in apoptosis of the
infected cell.
This model is based primarily on data generated using
the human carcinoma HEp-2 cell line (Moore et al., 1955),
now known to be a HeLa cell-derived strain (Chen, 1988;
Nelson-Rees et al., 1974) and referred to here as HEp-2/
HeLa. However, not all cell types display identical apoptotic
responses to HSV-1 infection. In our original study
describing HSV-1-dependent apoptosis, infected African
green monkey kidney Vero cells differed from HEp-2/HeLa
cells by their apparent inability to display abundant
morphological apoptotic features (Aubert and Blaho,
1999). Similarly, Gautier et al. reported that HSV-1 infected
Vero cells do not display an alteration in mitochondrial
membrane potential at 1 and 3 hpi (Gautier et al., 2003).
These results suggest that Vero cells fail to undergo efficient
HSV-1-dependent apoptosis. However, others have reported
that Vero cells infected with the HSV-1(d120) mutant virus
exhibit TUNEL positive staining, DNA laddering, and
nuclear changes at or after 24 hpi (Galvan et al., 1999;
Leopardi and Roizman, 1996; Leopardi et al., 1997).
This apparent discrepancy among studies led us to
specifically compare the HSV-1-dependent apoptosis of
Vero and HEp-2/HeLa cells and determine the underlying
causes behind these differences. We report the following.
Vero cells did exhibit specific apoptotic morphologies
following infection with either ICP27- or ICP4-null viruses,
but these features took longer to manifest than those of the
HEp-2/Hela cells. Vero cells required de novo protein
synthesis to undergo efficient HSV-1-dependent apoptosis
while HEp-2/HeLa cells did not. The required protein(s)
was synthesized prior to 3 hpi in vBSD27-infected Vero
cells. Viruses deleted for ICP4, ICP27, and ICP22 induced
Vero cell apoptosis, implying that either cellular or other
viral proteins are needed for this process to occur. These
results help to clarify our understanding of the cell type
differences in HSV-1-dependent apoptosis.Results
Vero and HEp-2/HeLa cells displayed temporal and
qualitative differences in the appearance of
HSV-1-dependent apoptotic morphologies
The first goal of this study was to carefully compare
HSV-1-dependent apoptosis in Vero and HEp-2/HeLa cells.
Among the evidence in support of Vero cells being
susceptible to HSV-1-dependent apoptosis was that DNA
laddering was observed at 24 and 30 h following infection
with the ICP4 and US3 null virus, d120 (Galvan et al., 1999;
Leopardi and Roizman, 1996; Leopardi et al., 1997). Our
M.L. Nguyen et al. / Virology 336 (2005) 274–290276laboratory reported that Vero cells infected with the ICP27-
null virus, vBSD27, fail to display DNA laddering at 15 hpi,
while vBSD27-infected HEp-2/HeLa cells exhibit maximum
DNA laddering at 12 hpi (Aubert and Blaho, 1999). The fact
that DNA laddering was detected by others later in Vero
cells than we observed in HEp-2/HeLa cells suggests that
HSV-1-dependent apoptosis is slower in Vero cells. To test
this idea, a time-course experiment was performed with both
cell lines. HEp-2/HeLa and Vero cells were infected with
HSV-1(KOS1.1) or vBSD27 virus at a multiplicity of
infection (MOI) of 10 in the presence and absence of
CHX, and morphological changes were assessed by phase-
contrast microscopy at 12, 24, and 36 hpi (Fig. 1).
As expected, HSV-1(KOS1.1) infection in the absence
of CHX led to increased cell size, rounded morphologies
(Fig. 1), and marginalization of chromatin in the nuclei
(data not shown) of both HEp-2/HeLa and Vero cells.Fig. 1. Morphological assessment of HEp-2/HeLa and Vero cells during HSV-1-de
HSV-1(KOS1.1) in the presence (+) or absence () of 10 Ag/ml CHX or ICP27-nu
light microscopy (magnification, 40) and photographed at 12, 24, and 36 hpi. Inse
of representative cells from each photo.These characteristics are indicative of CPE, which
accompanies productive HSV-1 infection. CPE was
evident at 12 hpi and reached a maximum by 24 hpi in
both cell lines. Consistent with previous reports from our
laboratory (Aubert and Blaho, 1999; Aubert et al., 1999),
HEp-2/HeLa cells infected with vBSD27 exhibited apop-
totic morphologies including a reduced overall cell size
and irregular membranes. This phenotype was present as
early as 12 hpi and reached its maximum at 24 hpi. In
contrast, vBSD27-infected Vero cells failed to exhibit
similar morphologies at 12 hpi. At 24 hpi, approximately
half of the vBSD27-infected Vero cells appeared smaller
and irregularly-shaped compared to mock-infected cells,
suggestive of apoptosis in these cells. Although the
number of Vero cells displaying altered morphologies
increased slightly from 24 to 36 hpi, they never reached
the level displayed by HEp-2/HeLa cells. These resultspendent apoptosis. Vero and HEp-2/HeLa cells were infected with wild-type
ll virus, vBSD27, at an MOI of 10. Cells were visualized by phase contrast
ts within the photos of the 24 hpi time points correspond to enlarged images
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similar to apoptotic cells when infected with vBSD27,
they do so to a much lower extent and with slower
kinetics than HEp-2/HeLa cells.
A more prominent distinction between the two cell lines
was revealed when protein synthesis was inhibited during
infection. Treatment with CHX alone induced a low-level,
background amount of apoptosis in mock-infected HEp-2/
HeLa cells, probably due to the depletion of preexisting
cellular survival factors that were not replenished when
protein synthesis was blocked. As expected, apoptosis was
drastically increased in KOS plus CHX-treated HEp-2/HeLa
cells compared to those only infected with KOS or treated
with CHX alone at all time points. In contrast, CHX-treated
Vero cells infected with KOS failed to display apoptosis-like
morphologies at 12 and 24 hpi. At 36 hpi, a small number of
the KOS plus CHX-infected Vero cells seemed to display
features of apoptosis, but this did not reach the extent of the
morphological changes observed with the vBSD27-infected
Vero cells.
This finding was quite unexpected. Unlike our results
with HEp-2/HeLa cells, there seemed to be some distinction
between these two treatments which allowed for HSV-1-
dependent apoptosis-like morphological changes of Vero
cells in one case (vBSD27) but not the other (KOS plus
CHX). One major difference is that cellular and some viral
protein synthesis likely occurred during vBSD27, but not
KOS plus CHX infection.Fig. 2. PARP cleavage of infected cells in the presence and absence of de novo
1(KOS1.1), vBSD27, or the ICP4 null virus, CgalD3, in the presence (+) or absen
24 hpi, the cells were scraped into the media, collected by centrifugation, and
immunoblot analysis with anti-PARP and anti-ICP27 monoclonal antibodies and an
molecular weight uncleaved (116) and 85,000 molecular weight cleaved product (
PARP cleavage (% cleav.) as described in Materials and methods.De novo protein synthesis was required for efficient
HSV-1-dependent apoptosis in Vero cells
We next set out to test if infected Vero cells displayed
other signs of apoptosis and to determine whether proteins
synthesized during vBSD27 infection might facilitate HSV-
1-dependent apoptosis in Vero cells. Four sets of experi-
ments were performed. Since PARP cleavage and chromatin
condensation are evident in cells undergoing HSV-1-
dependent apoptosis, but not cells dying via CPE (Aubert
and Blaho, 1999; Aubert et al., 1999, 2001), we initially
used these assays to quantitatively assess apoptosis in
infected Vero cells. In the first series, we determined
whether inhibition of protein synthesis suppressed HSV-1-
dependent PARP cleavage in Vero cells. Vero and HEp-2/
HeLa cells were infected with HSV-1(KOS1.1) or vBSD27
at an MOI of 5 in the presence or absence of CHX. As an
additional positive control for HSV-1-dependent apoptosis
(Aubert and Blaho, 2003), we also used a recombinant virus
defective for the immediate early protein ICP4 (also termed
IE3), CgalD3. At 12 and 24 hpi, infected cells were
harvested, whole cell proteins were extracted, and PARP
cleavage, as well as the presence of ICP27 and TK viral
proteins, was assessed by immunoblotting (Fig. 2) as
described in Materials and methods.
ICP27 was found in cells infected with HSV-1(KOS1.1)
and CgalD3, but not vBSD27 (lanes 3–6 and 10–12). In
Vero cells, TK was present at approximately the same levelsprotein synthesis. Vero and HEp-2/HeLa cells were infected with HSV-
ce () of 10 Ag/ml CHX as described in Materials and methods. At 12 and
subjected to whole cell protein extraction. 50 Ag of protein was used for
ti-thymidine kinase (TK) polyclonal antibody. The migration of the 116,000
85) is indicated in the right margin. NIH image was used to quantify the %
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vBSD27, but absent in lysates from cells infected with
CgalD3 (compare lane 4 with 2 and 3). In vBSD27-infected
HEp-2 cells, TK was detected at 24, but not 12 hpi (lane 11).
This result is consistent with our previous studies indicating
that viral proteins accumulate to higher levels in nonhuman
cells than in human cells (Aubert and Blaho, 1999; O’ Toole
et al., 2003). Treatment of the infected cells with CHX
greatly reduced the synthesis of all of the viral proteins
tested (lanes 6–8 and 14–16). These results confirm that the
HEp-2 and Vero cells were similarly infected in this
experiment and indicate that CHX treatment resulted in
the reduction of viral protein synthesis.
At 12 hpi, PARP cleavage was detectable in lysates
from HEp-2/HeLa cells infected with vBSD27 (34%) and
KOS plus CHX (9%) (Fig. 2, lanes 11 and 14). Less than
3% PARP cleavage was observed in the mock, mock plus
CHX, and HSV-1(KOS1.1)-infected HEp-2/HeLa cell
lysates (lanes 9, 10, and 13), as well as in all of the Vero
cell lysates (lanes 1–9) at this time point. At 24 hpi,
mock-infected Vero cells plus CHX displayed <1% PARP
cleavage (Fig. 2, lane 5) while similarly treated HEp-2/
HeLa cells showed 16% (lane 10). At this time point,
PARP was cleaved in the lysates of HEp-2/HeLa cells
infected with vBSD27 or CgalD3, 99% and 63%,
respectively (lanes 11 and 12). The presence of CHX did
not reduce the level of PARP cleavage in HEp-2/HeLa
cells infected with ICP27 (100%) or ICP4 (73%) deletion
viruses (compare lanes 15 and 16 with 11 and 12). KOS
plus CHX-treated HEp-2/HeLa cells displayed almost
complete PARP cleavage (97%) at 24 hpi (lane 14). In
contrast, PARP cleavage was only 14% in the lysates of
Vero cells infected with KOS plus CHX (lane 6). At this
time point, the lysates of vBSD27- or CgalD3-infected
Vero cells without CHX exhibited substantial (40% and
42%) PARP cleavage (compare lanes 3 and 4). The finding
that CgalD3-infected Vero cells demonstrate apoptotic
features suggests that Vero cells are generally sensitive to
HSV-1-triggered apoptosis and these observations are not
peculiar to vBSD27 infection. The presence of CHX
reduced PARP cleavage in vBSD27-infected Vero cells
from 40% to 20% (lanes 3 and 7) and abrogated (42% to
<1%) its cleavage in CgalD3-infected cells (compare lanes
4 and 8). The reduction of apoptosis during vBSD27 plus
CHX infection was comparable to that of KOS plus CHX
(20% and 14%, respectively). That the level of apoptosis
in CgalD3 plus CHX-infected cells was less than these
values likely reflects parental strain differences (Aubert
and Blaho, 2001; Goodkin et al., 2004). This particular
experiment has been repeated more than five times (data
not shown and additional data later in this study). CHX
treatment in vBSD27-infected Vero cells reproducibly led
to between a 2- and 5-fold reduction in PARP cleavage in
each instance. From these results, we conclude that de
novo protein synthesis is required for efficient HSV-1-
dependent PARP cleavage in Vero cells.In the second series of experiments, we assessed the role
of protein synthesis in HSV-1-dependent chromatin con-
densation. Vero and HEp-2/HeLa cells were infected in
triplicate with HSV-1(KOS1.1) and vBSD27 at an MOI of 5
in the presence or absence of CHX. At 24 hpi, Hoechst dye
was added to the media and 2–3 random microscopic (40)
fields per replicate were digitally captured. Representative
images are shown in Fig. 3A. The percentage of nuclei with
condensed chromatin (greater than 400 total cells analyzed
per treatment group) was assessed for each microscopic
field as described in Materials and methods. A statistical
analysis of the data was performed using Student’s t test.
The percentage of nuclei containing condensed chromatin is
presented in Fig. 3B.
34 T 4% of KOS plus CHX-infected HEp-2/HeLa cells
displayed chromatin condensation. In contrast, Vero cells
infected with KOS plus CHX (4 T 1%) exhibited the same
level of chromatin condensation as that of mock plus CHX
cells (4 T 2%). The levels of chromatin condensation
observed in vBSD27-infected HEp-2/HeLa in the presence
(63 T 12%) and absence (72T 5%) of CHX were
comparable. However, addition of CHX during vBSD27
infection reduced the percentage of nuclei containing
condensed chromatin in vBSD27-infected Vero cells from
55 T 12% to 8 T 4%. This difference between vBSD27-
infected Vero cells in the presence and absence of CHX was
determined to be statistically significant (P < 0.005).
Together, these findings indicate that the inhibition of
protein synthesis suppressed the development of HSV-1-
dependent chromatin condensation in Vero, but not in HEp-
2/HeLa cells.
Because DNA laddering was reported to occur at times
greater than 24 hpi during HSV-1-dependent apoptosis of
Vero cells (Galvan et al., 1999; Leopardi and Roizman,
1996; Leopardi et al., 1997), we set out in the third series to
validate these findings and to test whether protein synthesis
was important for this phenotype as well. HEp-2/HeLa and
Vero cells were mock-infected or infected with HSV-
1(KOS1.1), vBSD27, or CgalD3 in the presence and
absence of CHX. At 12, 24, and 36 hpi, cells were
harvested, low molecular weight DNAs were extracted,
separated in an agarose gel containing ethidium bromide,
and visualized by fluorescence enhancement using UV
illumination as described in Materials and methods (Fig. 4).
At 12 hpi, vBSD27-infected HEp-2/HeLa cells displayed
the highest level of obvious DNA ladders (Fig. 4, lane 3),
as expected (Aubert and Blaho, 1999). At 24 hpi, only the
mock- and HSV-1(KOS1.1)-infected HEp-2/HeLa cells
without CHX failed to yield the presence of low molecular
weight DNA (compare lanes 1 and 2 with 3–8). However,
these banding patterns seemed less distinct than that of
vBSD27-infected HEp-2/HeLa cells at 12 hpi, inasmuch as
the low molecular weight DNA had migrated as smears at
24 hpi. The progression from an obvious laddering pattern
at early times to a smear at late times during HSV-1-
dependent apoptosis was described earlier (Aubert and
Fig. 3. Chromatin staining (A) of Vero and HEp-2/HeLa cells at 24 hpi following infection with HSV-1(KOS 1.1) and vBSD27 viruses in the presence (+) or
absence () of 10 Ag/ml CHX. Hoechst DNA dye was added to the media at a concentration of 5 Ag/ml to allow for visualization of chromatin and cells were
photographed with a digital camera following fluorescent microscopy (magnification, 40). (B) Quantification of the percentage of nuclei with condensed
chromatin. This experiment was performed in triplicate. For each replicate experiment, the number of nuclei containing condensed chromatin was counted for
two to three (40) microscopic fields; at least 400 total nuclei. The bars indicate the average percentage of nuclei containing condensed chromatin. Error bars
signify the standard deviation for each treatment group. Statistical analysis of the difference between the vBSD27-infected Vero cells in the presence and
absence of CHX was performed using Student’s t test (**P < 0.005).
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weight DNA was detected in Vero cells at 12 hpi (lanes 9–
16). The mock- and HSV-1(KOS1.1)-infected Vero cells
plus CHX failed to demonstrate DNA laddering at 24 and
36 hpi (lanes 9 and 10, and 13 and 14). The observation
that KOS plus CHX did not show DNA laddering was
consistent with the absence of apoptotic morphologies and
reduced PARP cleavage in similarly-treated Vero cells
(Figs. 1, 2, and 3).
Obvious DNA laddering was detected at 24 hpi in
vBSD27- and CgalD3-infected Vero cells without CHX
(lanes 11 and 12). The pattern of this laddering did not
seem to change at 36 hpi in the absence of CHX; i.e., it
did not progress to a smear without detectable laddering.
Surprisingly, DNA laddering was detected with vBSD27-
and CgalD3-infected Vero cells in the presence of CHX
(lanes 15 and 16). It should also be noted that CHXtreatment did not completely ablate PARP cleavage in
vBSD27-infected Vero cells (Fig. 2). Together, these
findings suggest that a small number of apoptotic cells
may remain during infection with these deletion-mutant
viruses following treatment with CHX. Importantly, the
DNA laddering pattern did not change in these CHX-
treated infected cells between 24 and 36 hpi (lanes 15 and
16). Also, this amount of laddering never approached the
extent seen with HEp-2/HeLa cells at 24 (compare lanes
11–16 with 3–8) and 36 hpi (data not shown). This result
is in agreement with our earlier findings (Figs. 1 and 2)
that Vero cells exhibit slower kinetics of HSV-1-dependent
apoptosis than HEp-2/HeLa cells. Even though CHX
drastically reduced the level of apoptotic morphologies
and decreased the extent of PARP cleavage in Vero cells
infected with vBSD27 or CgalD3, it did not lead to a
profound decrease in the level of DNA laddering in these
Fig. 4. Fluorescence enhancement images of nucleosomal laddering of
chromosomal DNA. HEp-2/HeLa and Vero cells were infected with HSV-
1(KOS 1.1), vBSD27 (D27), or CgalD3 (D3), and low molecular weight
DNAs were extracted at 12, 24, and 36 hpi. Following extraction, DNAs
were separated in a 2% agarose gel containing 0.1 Ag/ml of ethidium
bromide and visualized under UV illumination as described in Materials
and methods.
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was not dramatically altered by CHX treatment. However,
DNA laddering detection is a nonquantitative assay and
the possibility remains that it may require complete
prevention of apoptosis throughout the course of infection
(as in mock- and KOS-infected cells) to score negatively.
Many investigators have shown that HSV-1 infection
changes the composition and function of mitochondria
(Galvan et al., 2000; Gautier et al., 2003; Murata et al.,
2000; Radsak and Albring, 1974; Radsak and Freise, 1972;
Zhou and Roizman, 2000). During apoptosis, mitochondrial
membrane potential (Dwm) disruption plays a key role in the
induction of the intrinsic pathway and is important for
amplification of the extrinsic apoptotic pathway (reviewed
in Ly et al., 2003). One recent study reported that HSV-infected neuron-like cells exhibit a disruption of Dwm at
3 hpi (Gautier et al., 2003). At this time point, these
researchers did not detect a similar disruption in HSV-
infected Vero cells. To determine if changes in Dwm occur
later during HSV-1-dependent apoptosis of Vero cells and to
examine the role of protein synthesis in this process, we
performed the following fourth set of experiments. HEp-2/
HeLa and Vero cells were mock-infected or infected with
vBSD27 at an MOI of 5 in the presence and absence of
CHX. At 24 and 28 hpi, the cells were harvested and
assessed for Dwm using the MitoCapture assay as described
in Materials and methods.
MitoCapture reagent aggregates in the mitochondria of
healthy cells and fluoresces red. In apoptotic cells, the
MitoCapture reagent cannot penetrate mitochondria due to
their disrupted mitochondrial membrane potential. There-
fore, the reagent stays in its monomeric form in the
cytoplasm and fluoresces green.
Using flow cytometry, we measured the red (data not
shown) and green fluorescence for each cell. Representative
histograms of the green (FL-1 channel) fluorescence
intensity (F. I.) of Vero cells at 24 hpi are shown in Fig.
5. The single distribution observed in mock-infected cells
represents F. I. of the MitoCapture Reagent (background
fluorescence) in healthy cells (3%). Cells infected with
vBSD27 displayed a bimodal F. I. distribution, indicative of
a fraction of these cells undergoing apoptosis (Fig. 5C). The
peak with the F. I. greater than that of background
corresponds to cells with disrupted Dwm. The areas under
these curves were used to determine the percentage of cells
with disrupted Dwm (Fig. 5 and Table 1) as described in
Materials and methods.
At 24 hpi, approximately 50% of vBSD27-infected cells
displayed disrupted Dwm in both cell lines (Fig. 5C and
Table 1). CHX treatment of mock-infected HEp-2/HeLa or
Vero cells at 24 hpi did not significantly alter the percentage
displaying disrupted Dwm compared to mock without CHX
cells (Fig. 5 and Table 1). The addition of CHX during
vBSD27 infection led to a decrease in the percentage of
Vero cells exhibiting Dwm disruption from 46% to 20%
(compare Figs. 5C with D). In contrast, CHX treatment of
the vBSD27-infected HEp-2/HeLa cells did not lead to a
reduced Dwm disruption (51% and 57%) (Table 1). Similar
results were observed when Dwm was measured at 28 hpi
(Table 1). Thus, inhibition of protein synthesis led to a
reduced disruption of Dwm in vBSD27-infected Vero cells,
but not HEp-2/HeLa cells. This indicates that protein
synthesis is required for vBSD27 to optimally disrupt the
Dwm of Vero cells.
Taken together, the results from Figs. 1–5 and Table 1
illustrate several aspects of HSV-1-dependent apoptosis in
Vero cells. First, apoptosis was induced in infected Vero
cells, but we observe it at a much lower extent than that of
HEp-2/HeLa cells. This observation of apoptosis in infected
Vero cells is consistent with the results of others (Galvan
and Roizman, 1998). Second, a significant kinetic distinc-
Fig. 5. Flow cytometry analysis of MitoCapture assay. Vero cells were mock (A–B)-infected or infected with vBSD27 (C–D) in the presence (B and D) or
absence (A and C) of 10 Ag/ml CHX. At 24 hpi, adherent and floating cells were harvested and assessed for mitochondrial membrane potential (Dwm) using the
MitoCapture assay as described in Materials and methods. In apoptotic cells, MitoCapture monomers were detected in the FL1 channel of a flow cytometer.
Graphic representations of MitoCapture monomer fluorescence intensity (F. I.) are displayed. The area under the curve that displays a peak monomer F. I.
greater than that of mock was used to define the percentage of cells with disrupted Dwm (numbers beside each graph). The results shown in this figure are
representative of the data used to generate Table 1.
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HEp-2/HeLa cells to HSV-1 infection. Finally, Vero cells,
but not HEp-2/HeLa cells, require de novo protein synthesis
to undergo efficient HSV-1-dependent apoptosis.Table 1
Inhibition of protein synthesis reduces HSV-dependent disruption of
mitochondrial membrane potential
Percentage of cells with disrupted mitochondrial
membrane potential (Dwm)
24 hpi 28 hpi 28 hpi
Vero
Mock 2.6 7.5 11.7
Mock + CHX 4.0 3.7 6.7
D27 46.0 35.0 42.8
D27 + CHX 20.3 18.4 27.4
HEp-2/HeLa
Mock 6.8 25.1
Mock + CHX 7.0 17.9
D27 50.6 64.0
D27 + CHX 57.2 71.9Protein synthesis prior to 3 hpi was required for efficient
HSV-1-dependent apoptosis in Vero cells
We next set out to define the time period during HSV-1
infection that de novo protein synthesis was required for
optimal apoptosis to occur in Vero cells. To accomplish this,
Vero cells were infected with vBSD27 in intervals such that
the infections were allowed to progress for 0, 1, 2, 3, and 5 h
before de novo protein synthesis was blocked by the
addition of CHX (Fig. 6A). Our prediction was that if
CHX is added after the proteins required for HSV-1-
dependent apoptosis had been synthesized, then CHX
addition would not affect the level of apoptosis observed
with vBSD27 infection in Vero cells. Concurrent infections
were performed without the addition of CHX, as controls.
At 24 h following CHX treatment, Hoechst dye was added
to the media and microscopic images were captured to
assess chromatin condensation (Fig. 6B). Subsequently, the
cells were harvested, proteins were extracted, and immuno-
blotting analyses were performed using anti-PARP antibody
(Fig. 6C).
Fig. 6. Schematic representation (A), chromatin staining (B), and PARP cleavage (C) identifying the time frame in which proteins must be synthesized for
HSV-1-dependent apoptosis. Infections were staggered such that CHX addition (stop sign containing ‘‘C’’) would block de novo protein synthesis in vBSD27-
infected (circle containing ‘‘D’’) Vero cells at 0, 1, 2, 3, and 5 hpi. 24 h following the time of CHX treatment (T = 0), Hoechst dye was used to visualize
condensed chromatin and whole cell extracts (square containing ‘‘H’’) were prepared. As controls, extracts were also prepared from mock- and vBSD27-
infected Vero cells which were not treated with CHX. (B) Cells were photographed at 24 hpi with a digital camera following phase-contrast light (Phase) and
fluorescent (Hoechst) microscopy (magnification, 40). Numbers represent the percentage of nuclei in the panel field with condensed chromatin. (C) Immune
reactivities of vBSD27-infected Vero cell electrophoretically separated extracts with (+) and without () CHX treatment. 50 Ag of protein was used for
immunoblot analysis with anti-PARP monoclonal antibody. The migration of the 116,000 molecular weight uncleaved (116) and 85,000 molecular weight
cleaved product (85) is indicated. NIH image was used to quantify the percent PARP cleavage (% cleav.) as described in Materials and methods.
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addition at 0 and 1 hpi led to a reduction in chromatin
condensation (7% and 13%, respectively) in the vBSD27-
infected cells (Fig. 6B) compared to that without CHX
(43% and 40%). Similarly, PARP cleavage in the
presence of CHX at these times was also reduced (33%
and 29%) compared to that without CHX (78% and 77%)
(Fig. 6C, compare lanes 4 and 6 with 3 and 5). When
CHX was added at 2 hpi (Fig 6C, compare lanes 7 and
8), there was a modest reduction in PARP cleavage(50%) compared to vBSD27-infected cells without CHX
(81%), as well as a reduction in chromatin condensation
from 46% to 11% (Fig. 6B). At 3 and 5 hpi, there was
little to no reduction in PARP cleavage (67% and 69%,
respectively) or chromatin condensation (37% and 28%)
in the CHX-treated cells (Figs. 6B and C, lanes 11–12)
compared to the controls (76% and 69% for PARP; 51%
and 28% for chromatin condensation). We have also
performed a similar experiment in which the harvest time
was staggered and the infection time kept constant for all
M.L. Nguyen et al. / Virology 336 (2005) 274–290 283treatment groups, and this analysis yielded similar results
(data not shown). Based on these results, we conclude
that the initiation of synthesis of protein(s) required for
efficient HSV-1-dependent apoptosis in Vero cells occurs
prior to 3 hpi and these factors are completely active by
5 hpi.
Synthesis of full-length ICP22 and US1.5 were not required
for efficient HSV-1-dependent apoptosis in Vero cells
The finding that the proteins necessary for efficient HSV-
1-dependent apoptosis in Vero cells are synthesized by 3 hpi
suggests that either cellular proteins or IE viral proteins
might play a role in the process. Our results showing
reductions in PARP cleavage upon CHX treatment with
vBSD27 or CgalD3 viruses indicate that the ICP27 and
ICP4 IE proteins are not required for HSV-1-dependent
apoptosis in Vero cells. Recent studies have shown that
US1.5, a truncated, carboxyl-terminal version of ICP22 that
begins at amino acid 147 (Carter and Roizman, 1996), can
activate caspase 3 if it is highly expressed using a
baculovirus vector (Hagglund et al., 2002). To determine
whether US1.5 or ICP22 is required for HSV-1-dependent
apoptosis in Vero cells, we utilized the HSV-1(DMP) virus
which does not synthesize full-length ICP27 or ICP22 (Wu
et al., 1996). In HSV-1(DMP), the open reading frame
encoding ICP27 is deleted (McCarthy et al., 1989) and a
termination codon is inserted at amino acid 199 of the 420
amino acid-long ICP22, thus producing truncated forms of
ICP22 (Rice et al., 1995) and US1.5. A virus containing the
n199 ICP22 mutant allele (Post and Roizman, 1981)
exhibited a growth deficiency similar to that seen with a
complete ICP22 knockout (Poffenberger et al., 1993),
indicating that if any truncated proteins are produced, they
are likely to be inactive. Vero cells were mock-, HSV-
1(KOS1.1)-, vBSD27-, or HSV-1(DMP)-infected at an MOI
of 5 in the presence and absence of CHX. At 24 hpi, nuclear
and cellular morphologies (Fig. 7A) and the extents of
PARP cleavage (Fig. 7B) were determined. To monitor viral
infection, we also immunoblotted for ICP4, ICP27, and TK
viral proteins.
As expected, KOS-infected cells displayed abundant
levels of ICP4, ICP27, and TK, and CHX greatly reduced
the levels of these proteins (compare lanes 3 and 4). ICP4
and TK, but not ICP27, were evident in vBSD27- and
DMP-infected cells (lanes 5 and 7). Surprisingly, the
levels of ICP4 and TK proteins were higher in Vero cells
infected with DMP than those infected with the vBSD27
virus. The basis for this difference is unknown at this
time.
In this experiment, the presence of CHX during
vBSD27 infection decreased the level of chromatin
condensation from 37% to 5% (Fig. 7A). Similarly, CHX
treatment led to a reduction in PARP cleavage (from 44%
to 8%) in vBSD27-infected cells (Fig. 7B, compare lane 6
with 5). Sixty-five percent of the cells infected with HSV-1(DMP) in the absence of CHX showed chromatin
condensation (Fig. 7A) and the percentage of PARP
cleavage exhibited by this group was 60% (Fig. 7B, lane
7). These findings, alone, suggest that the proteins required
for HSV-1-dependent apoptosis in Vero cells are produced
during HSV-1(DMP) infection. Furthermore, CHX addition
to HSV-1(DMP)-infected cells led to a dramatic reduction
in chromatin condensation (from 65% to 5%) and PARP
cleavage (from 60% to 9%) (Fig. 7, compare lanes 7 and
8). Based on these results, we conclude that full-length
ICP22 and US1.5 are not required for HSV-1-dependent
apoptosis in Vero cells.Discussion
Initial characterizations of HSV-1-dependent apoptosis
mainly utilized the HEp-2/HeLa cell line. Since that time,
several cell type-dependent differences in this apoptotic
response have been reported. Here, we examined the
differences between HSV-1-dependent apoptosis in HEp-2/
HeLa and Vero cells. The significant features of our findings
may be summarized as follows.
Vero cells undergo HSV-1-dependent apoptosis with delayed
kinetics compared to HEp-2/HeLa cells
The finding that Vero cells in fact do undergo apoptosis,
albeit later than HEp-2/HeLa cells, is consistent with
reports showing that Vero cells display nucleosomal DNA
cleavage at 24 and 30 hpi when infected with the ICP4-,
US3-null virus, d120 (Galvan et al., 1999; Leopardi and
Roizman, 1996; Leopardi et al., 1997). One explanation for
the delayed response of Vero cells to HSV-1-dependent
apoptosis could be that the virus grows more slowly in Vero
cells. However, Vero cells accumulate viral proteins at a
slightly higher rate than HEp-2/HeLa cells during wild-type
HSV-1 infections (Fig. 2 and Aubert and Blaho, 1999;
O’Toole et al., 2003). Furthermore, wild-type HSV-1 has
been reported to grow to between 2 and 5 times higher
titers in Vero cells as compared to HEp-2/HeLa cells during
the same time period, suggesting that the virus grows
quicker in Vero cells (Petrovskis et al., 1988; Visalli and
Brandt, 1991). Therefore, the distinction in the kinetics of
apoptosis is unlikely to be due to a general viral replication-
cycle effect.
Although the difference in apoptotic kinetics between
Vero and HEp-2/HeLa cells seems subtle, it may be
biologically significant (Blaho, 2004). Two major mecha-
nisms are used by viruses to circumvent the apoptotic
responses of host cells (reviewed in Koyama et al., 2003).
Some viruses, such as influenza and vesicular stomatitis
viruses, replicate quickly and complete their progeny virion
production before the onset of apoptotic cell death
(Koyama, 1995; Kurokawa et al., 1999). Other viruses,
such as adenoviruses and poxviruses, encode viral proteins
Fig. 7. Cellular morphologies (A) and immune reactivities (B) of HSV-1(DMP)-infected Vero cells. (A) Vero cells were infected with HSV-1(KOS 1.1),
vBSD27(D27), or HSV-1(DMP) in the presence (+) or absence () of 10 Ag/ml CHX. Hoechst DNA dye was added to the media at a concentration of 5 Ag/ml
to allow visualization of chromatin. Cells were photographed at 24 hpi with a digital camera following phase-contrast light (Phase) and fluorescent (Hoechst)
microscopy (magnification, 40). Numbers represent the percentage of nuclei in the panel field with condensed chromatin. (B) The cells in panel A were
extracted and 50 Ag total protein was separated in a denaturing gel and analyzed by immunoblotting using anti-PARP, anti-ICP4, and anti-thymidine kinase
(TK) antibodies. The migration of the 116,000 molecular weight uncleaved (116) and 85,000 molecular weight cleaved (85) PARP products is indicated.
Percent PARP cleavage (% cleav.) was calculated as described in Materials and methods.
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and McFadden, 2002; White, 2001). In Vero cells, the HSV-
1 life cycle takes about 18 h to complete. We have shown
here that apoptosis is not detected in Vero cells until 24 hpi.
This result, along with the fact that HSV-1 encodes
antiapoptotic proteins, suggests that in Vero cells, HSV-1
may use both of the strategies described above, i.e., rapid
multiplication and antiapoptotic gene production, to evade
host cell apoptosis.Vero cells require de novo protein synthesis to undergo
efficient HSV-1-dependent apoptosis while HEp-2/HeLa
cells do not
This represents another significant distinction between
the HSV-1-dependent apoptosis of Vero and HEp-2/HeLa
cells; evidenced by the very low level of apoptosis in KOS
plus CHX-treated Vero cells and the reduction in vBSD27-
and CgalD3-induced apoptosis in Vero cells with CHX
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decrease in DNA laddering in vBSD27- or CgalD3-infected
Vero cells when treated with CHX even though apoptotic
morphologies, mitochondrial membrane potential disrup-
tion, and PARP cleavage were reduced. Instead, the extent
and patterning of laddering were unchanged from 24 to
36 hpi under these conditions. One explanation for this
might be that DNA laddering is a sensitive but non-
quantitative assay, in which low levels of apoptotic cells are
readily detected. Also, the presence of CHX led to a great
reduction, but not complete inhibition of apoptotic mor-
phologies, mitochondrial membrane disruption, and PARP
cleavage in vBSD27- or CgalD3-infected cells. Perhaps the
low numbers of Vero cells that are undergoing apoptosis
under these conditions are enough to make the population
score positively in the DNA laddering assay. This is
supported by the observation that mock-infected HEp-2/
HeLa in the presence of CHX cells displayed a modest level
of nucleosomal laddering at 24 hpi even though less that
10% of the cells displayed other apoptotic phenotypes at this
time point. Alternatively, it may be possible in these cells to
prevent caspase activities and apoptotic morphological
changes without inhibiting nucleosomal DNA cleavage.
Proteins synthesized prior to 3 hpi are required for efficient
apoptosis in infected Vero cells
This suggests that the synthesis of either cellular or viral
protein(s) is necessary for HSV-1-dependent apoptosis in
Vero cells, and our results indicate that ICP27, ICP4, full-
length ICP22, and US1.5 are not required. These findings
are perhaps not surprising since earlier studies have shown
that ICP4 (Aubert and Blaho, 2003; Leopardi and Roizman,
1996), ICP27 (Aubert and Blaho, 1999), and ICP22 (Aubert
et al., 1999) are needed for efficient apoptosis prevention. It
should be noted that the data showing an antiapoptotic role
for ICP22 utilized a recombinant virus containing a deletion
mutation that also disrupted the US1.5 open reading frame.
As the ICP4-null d120 virus also contains a deletion of the
US3 gene (Leopardi et al., 1997) and this virus triggers
apoptosis in Vero cells (Leopardi and Roizman, 1996), we
must conclude that US3 is also not required for HSV-1-
dependent apoptosis in these cells. Since US3 is a late gene
(Roizman and Knipe, 2001), this conclusion is consistent
with our finding that the required protein(s) is produced
prior to 3 hpi. This leaves open the possibility that synthesis
of ICP0 and/or ICP47 viral proteins may participate in HSV-
1-dependent apoptosis in Vero cells. However, it should be
noted that data have recently been published which imply an
antiapoptotic function for the ICP0 protein, due to its ability
to ubiquitinate p53 and target it for degradation (Boutell and
Everett, 2003).
Alternatively, cellular protein synthesis may be required
for HSV-1-dependent apoptosis in Vero cells. If this is the
case, the required cellular proteins most likely induce
apoptosis as an antiviral response. At least two previousstudies from our laboratory are consistent with a host
antiviral role for apoptosis; in each, apoptosis prevention
during HSV-1 infection increases the accumulation of viral
gene products. First, the addition of the caspase 3 inhibitor,
Z-DEVD-fmk, to vBSD27-infected HEp-2/HeLa cells
increases the steady state level of IE ICP4 protein (Aubert
et al., 1999). Second, inducing antiapoptotic pathways by
addition of the phorbol ester PMA in vBSD27-infected
HEp-2/HeLa cells increases the level of ICP4 accumulation
(Goodkin et al., 2003). Still, the cellular mechanisms that
mediate antiviral apoptosis induction remain unclear.
Interestingly, infection of HeLa or baby hamster kidney
cells with replication-defective mutants of HSV-1 was
reported to reduce levels of antiapoptotic bcl-2 in a
p38MAPK-dependent manner (Zachos et al., 2001). This
result might provide examples of cellular proteins that may
participate in the induction of apoptosis during HSV-1
infection.
Potential host factors that mediate the requirement for
protein synthesis during HSV-1-dependent apoptosis
Our results indicate that Vero cells require protein
synthesis for efficient HSV-1-dependent apoptosis while
HEp-2/HeLa cells do not. HEp-2/HeLa and Vero cells
possess a number of different properties that could account
for this distinction. HEp-2 cells were initially reported to be
derived from a human laryngeal carcinoma (Moore et al.,
1955) and subsequent studies have demonstrated that those
obtained from the ATCC represent a HeLa cell contami-
nation (Chen, 1988; Nelson-Rees et al., 1974; Ogura et al.,
1993). Regardless, HEp-2/HeLa cells remain a trans-
formed, human, epithelial cell line. In contrast, Vero cells
were generated through the sequential passage of adult
African green monkey kidney cells (Rhim et al., 1969), and
they are a nontransformed, primate, fibroblast cell line.
This raises the possibility that differences in species, tissue
origin, or oncogenic transformation status may be respon-
sible for the distinct responses of Vero and HEp-2/HeLa
cells to HSV-1-dependent apoptosis. However, recent
preliminary experiments in our laboratory demonstrate that
a nontransformed human epithelial cell line also requires
protein synthesis for HSV-1-dependent apoptosis (unpub-
lished data). This suggests that the requirement for protein
synthesis during HSV-1-dependent apoptosis is not specific
to primate or fibroblast cells. We are currently examining
the role of oncogenic transformation status in defining the
requirement for protein synthesis during HSV-1-dependent
apoptosis.
Alternatively, the distinction between the apoptotic
responses of HEp-2/HeLa and Vero cells may be more
specific to HSV infection. HSV has recently been shown
to enter Vero and HeLa cells through different pathways
(Nicola et al., 2003; Nicola and Straus, 2004). HSV may
enter HeLa and Chinese hamster ovary cells through an
endocytic mechanism, while it enters Vero cells through
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also enters HEp-2/HeLa cells through an endocytic
mechanism. Regardless, we have previously shown that
like HEp-2/HeLa cells, S3 HeLa cells are capable of
undergoing HSV-dependent apoptosis in the absence of de
novo protein synthesis (Aubert and Blaho, 2003). There-
fore, it is possible that the different requirements for
protein synthesis during HSV-dependent apoptosis are
mediated by different entry mechanisms. Yet, it is not
known at this time how endocytosis entry of HSV would
substitute for the requirement for protein synthesis during
HSV-dependent apoptosis.
In summary, the data included in this report provide an
explanation for the different apoptotic responses of HEp-2/
HeLa and Vero cells to HSV-1 infection. Differences in
HSV-1-dependent apoptosis have been reported for a
number of cell types including human corneal epithelial
(Miles et al., 2003), mouse embryo fibroblast (Aubert and
Blaho, 2003), and human neuroblastoma (Galvan and
Roizman, 1998) cells. Similar temporal delays and differ-
ential requirements for protein synthesis might explain the
differences observed in the HSV-1-dependent apoptosis of
these and other cell types. Consideration of our findings
would be beneficial to those characterizing virus–host
interactions as they emphasize the impact of cell type
differences in experimental systems.Materials and methods
Cells and viruses
HEp-2/HeLa and Vero cells were obtained from the
American Type Culture Collection (Rockville, MD) and
maintained in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 5% fetal bovine serum.
Although HEp-2 cells were originally developed from a
patient with laryngeal carcinoma (Moore et al., 1955), it
was later recognized that current isolates provided by the
ATCC are HeLa cell contaminants (Chen, 1988; Nelson-
Rees et al., 1974). For this reason, we refer to them as
HEp-2/HeLa cells. Vero 2.2 (Heeg et al., 1986) and FO6
(Samaniego et al., 1997) cells are derivatives of Vero cells
expressing either ICP27 alone or ICP27, ICP4, and ICP0
from their own promoters, respectively. HSV-1(KOS1.1)
was the strain of wild-type HSV-1 used in this study. HSV-
1(CgalD3) and HSV-1(vBSD27) viruses were generously
provided by Theodore Friedmann and Saul Silverstein,
respectively. vBSD27 is an ICP27-null virus derived from
HSV-1(KOS 1.1) containing a replacement of the a27
gene with the Escherichia coli lacZ gene (Soliman et al.,
1997). This virus was propagated and tittered on Vero 2.2
(gift of Saul Silverstein). CgalD3 was derived from the
HSV-1(17syn+) strain and is an IE3 (ICP4)-null virus
which is deleted for 3.6 kb of the coding region of IE3
(Paterson et al., 1990) due to having the Escherichia colilacZ gene inserted into the BamHI Z fragment (Johnson et
al., 1992). The HSV-1(DMP) virus was generously
provided by Neal DeLuca and is derived from HSV-
1(KOS1.1) (Wu et al., 1996). In HSV-1(DMP), the open
reading frame encoding ICP27 is deleted (McCarthy et al.,
1989) and a termination codon was inserted at amino acid
199 of the 420 amino acid long ICP22 (Rice et al., 1995).
CgalD3 and DMP viruses were propagated and tittered on
FO6 cells (gift of Neal DeLuca). Cell monolayers
(approximately 6  106) were infected at a multiplicity
of infection (MOI) of 10, unless otherwise noted, and
allowed to proceed at 37 -C in growth media for the times
indicated in the text. In experiments designed to inhibit
protein synthesis, cycloheximide (CHX) was added
directly to the media at a concentration of 10 Ag/ml 1 h
prior to infection (excluding the time course) and main-
tained at that level until the time of harvest. Unless
otherwise noted, all cell culture reagents were obtained
from Life Technologies and all biochemicals from Sigma.
Whole cell protein extractions and immunoblotting
Whole cell extractions of infected cells were performed
as follows. Cells were scraped into the medium, collected
by centrifugation for 5 min at 1000  g, and washed
once in cold phosphate-buffered saline (PBS). Cells were
lysed by resuspending in RIPA buffer (50 mM Tris–HCl,
pH 7.5, 150 mM NaCl, 1% Triton X100, 1% deoxy-
cholate, 0.1% SDS) supplemented with 2 mM phenyl-
methylsulfonyl fluoride (PMSF, freshly prepared stock),
1% Translysol, 0.1 mM l-I-chloro-3-(4-tosulamido)-4-
phenyl-2-butanone (TPCK), 0.01 mM l-1-chlor-3-(4-tosy-
lanmido)-7-amino-2-heptanon-hydrochloride (TLCK), and
vortexed for 30 s. The cell lysates were cleared by
centrifuging for 10 min at 4 -C at 16,000  g. Protein
concentrations were determined using a modified Bradford
protein assay (Bio-Rad Laboratories). 50 Ag of total
protein was separated on 15% N,NV-diallyltartardiamide-
acrylamide gels and electrically transferred to nitrocellu-
lose using a tank apparatus (Bio-Rad Laboratories).
Membranes were blocked for 1 h at room temperature
in PBS containing 5% nonfat dry milk and incubated
overnight at 4 -C in primary antibody. The monoclonal
anti-ICP4, 1114, (Goodwin Institute for Cancer Research,
Plantation, FL.), monoclonal anti-ICP27, 1113, (Good-
win), monoclonal anti-PARP (Pharmingin), and polyclonal
anti-thymidine kinase (TK) antibodies were diluted at a
concentration of 1:1000 in Tris-buffered saline containing
0.1% Tween 20 (TBST) and 0.1% BSA. After washing in
TBST, membranes were incubated with either anti-mouse
or anti-rabbit antibodies conjugated to alkaline phos-
phatase (Southern Biotech) diluted in blocking buffer
(1:1000) for 1 h at room temperature. Following washing
in TBST, immunoblots were developed in buffer contain-
ing 5-bromo-4-chloro-3-indolyl phosphate and 4-nitro-
bluetetrazolium chloride.
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To quantitate the percentage of total infected cell PARP
that is cleaved, densitometry of immune reactive PARP was
performed as described (Aubert et al., 1999). NIH image
version 1.63 was used to measure the integrated density (ID)
of the 116,000 molecular weight uncleaved and 85,000
molecular weight cleaved PARP bands. These values were
used to calculated the % PARP cleavage (cleav.) for each
lane using the following formula: % cleav. = {(cleaved
PARP ID)/(cleaved PARP ID plus uncleaved PARP ID)} 
100%.
DNA laddering assay
Nucleosomal cleavage of cellular DNA was assessed
essentially as described previously (Aubert and Blaho,
1999; Koyama and Miwa, 1997). Briefly, cells were scraped
into the medium, collected by centrifugation for 5 min at
1000  g, and washed once in cold PBS. Following
suspension in 100 Al of PBS, the cells were lysed by the
addition of 400 Al of 10 mM Tris–HCl, pH 7.4, 10 mM
EDTA containing 0.6% SDS. Lysates were mixed with
125 Al of 5 M NaCl and after overnight incubation at 4 -C,
the solution was centrifuged for 30 min at 16,000  g to
pellet chromosomal DNA. The supernatant was then
subjected to treatment with 0.1 mg/ml RNAse A (37 -C
for 1 h) and 1 mg/ml Proteinase K (50 -C for 2 h), followed
by sequential phenol/chloroform extractions and precipita-
tion in ethanol. The precipitated DNA was resuspended in
water. Subsequently, the entire sample volume was sepa-
rated in a 2% agarose gel using 89 mM Tris-borate, pH 8.3,
2 mM EDTA running buffer containing 0.1 Ag/ml ethidium
bromide and visualized using UV illumination.
Microscopic analysis, image capture, and quantification of
chromatin condensation
The morphologies of infected cells were visualized by
phase contrast and fluorescence light microscopy and
documented using an Olympus IX70/IX-FLA inverted
fluorescence microscope. Images were acquired with a
Sony DKC-5000 digital camera linked to a PowerMac
workstation and processed through Adobe Photoshop. For
chromatin condensation analysis, 5 Ag/ml Hoechst 33258
(Sigma) was added to the media. Quantification of
chromatin condensation was determined by counting the
number of brightly stained, small nuclei in several micro-
scopic fields. The percentage of nuclei containing con-
densed chromatin was determined using two independent
methods. (i) As an initial gauge of apoptosis, infected cells,
which were to be extracted for later immunoblotting studies,
were analyzed. The nuclei of these cells containing
condensed chromatin were counted in a particular (40)
microscopic field. These numbers are presented as percen-
tages displayed within panels in figures showing Hoechst-stained nuclei. It should be noted that fields counted are
slightly larger than the displayed images. At least 100 total
nuclei were counted per treatment group. (ii) To specifically
determine the significance of changes in chromatin con-
densation observed upon CHX addition, detailed counting
experiments were performed in triplicate. The percentage of
nuclei with condensed chromatin was assessed in two to
three (40) fields per replicate. This resulted in the counting
of over 400 nuclei per treatment group. Values from the
three experiments were averaged, standard deviations
calculated, and statistical analysis was then performed using
the two-sided Student’s t test.
MitoCapture assay
Following infection and/or CHX treatment, cell culture
media were removed and reserved. Adherent cells were
removed from culture vessels by rinsing once in PBS, then
incubating in a 0.5 mg/ml Trypsin, 0.53 mM EDTA
solution, and dislodged by repeat-pipetting. The trypsinized
cells were then combined with the media which had been
removed from the culture vessel. Cells from media and
monolayers were then collected by centrifuging for 5 min at
500  g and washed once with PBS. Next, cells with
disrupted mitochondrial membrane potential were identified
using the MitoCapture Kit (BioVision), as per the manu-
facturer’s instructions. Briefly, approximately 6  106 of
harvested/washed cells were suspended in 1 ml of diluted
MitoCapture reagent and incubated at 37 -C for 20 min. The
labeled cells were centrifuged at 500  g for 5 min. The
pellet was suspended in 1 ml of prewarmed MitoCapture
buffer. In healthy, nonapoptotic cells, the MitoCapture
reagent aggregates in mitochondria and fluoresces in the
red spectra. When the mitochondrial membrane potential is
disrupted in apoptotic cells, the MitoCapture reagent
remains in the cytoplasm as monomers. These monomers
fluoresce in the green spectra. MitoCapture-labeled cells
were analyzed for green (in the FL1 channel) and red (in the
FL2 channel) fluorescence using a Beckman Coulter
Cytomics FC500 flow cytometer. The percentage of cells
with disrupted mitochondrial membrane potential was
determined using Cytometics RXR flow cytometry software
and these fluorescence intensities (both FL1 and FL2) were
plotted. In control studies, staurosporine-treated, apoptotic
HEp-2 and Vero cells labeled with MitoCapture reagent
displayed an increase in FL1 fluorescence intensity and a
decrease in FL2 fluorescence intensity compared to
untreated controls (data not shown). Since the change in
signal intensity is greater in the FL1 (green) channel due to
the intrinsic nature of the MitoCapture reagent, the non-
apoptotic and apoptotic populations are more readily
discerned using this channel. Thus, we focused our analysis
on the FL1 channel. Accordingly, cells with reduced FL1
fluorescence were defined as cells with disrupted mitochon-
drial membrane potential. The low level FL1 fluorescence
intensity peak observed in mock-treated cells corresponds to
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it is inside healthy cells. The distribution of cells with peak
FL1 fluorescence intensity greater than that of this back-
ground fluorescence was defined as the distribution of cells
with disrupted mitochondrial membrane potential (disrupted
Dwm curve). This curve was used to calculate the percentage
of cells with disrupted Dwm using the following equation: %
cells with disrupted Dwm = area under the disrupted Dwm
curve/(area under disrupted Dwm curve + area under
background curve)  100%.
During the course of this study, we have attempted to set
up Annexin V staining and low molecular weight monitor-
ing procedures with FACS analysis in our laboratory.
However, as of yet, we have not been able to optimize the
assays to our satisfaction. We believe this is mainly due to
the inherent complications with using adherent cells (such
as Veros and Hep-2/HeLa cells) in flow cytometry analysis.Acknowledgments
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